Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination

  • 4 views
  • 06 May, 2022
  • 1 location
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)

This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with

  • 0 views
  • 28 Jul, 2022
  • 4 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment

  • 18 views
  • 07 Feb, 2022
  • 13 locations
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. To evaluate the antitumor activity of …

  • 0 views
  • 14 Jun, 2022
  • 14 locations
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid

BRAF
braf inhibitor
cancer
NRAS
  • 0 views
  • 09 Aug, 2022
  • 17 locations
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.

NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

advanced melanoma
immunologic adjuvant
melanoma skin
malignant melanoma of skin
NRAS
  • 1 views
  • 12 Jul, 2022
  • 24 locations
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who

mek inhibitor
trametinib
metastatic melanoma
targeted therapy
NRAS
  • 0 views
  • 28 Jul, 2022
  • 1 location
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)

Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of

advanced melanoma
trametinib
metastatic melanoma
metastasis
solid tumour
  • 7 views
  • 05 Feb, 2022
  • 1 location
HL-085 in NRAS-mutated Advanced Melanoma

NRAS mutation.

advanced melanoma
NRAS
alopecia
  • 0 views
  • 23 Mar, 2022
  • 2 locations
OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

This study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be

mek inhibitor
gilbert's syndrome
metastatic melanoma
metastasis
NRAS
  • 0 views
  • 04 Jul, 2022